These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36477882)

  • 1. Inclusions in macrophages of the cerebrospinal fluid during treatment with Tofersen.
    Sparasci D; Castelli C; Staedler C; Gobbi C; Ripellino P
    Muscle Nerve; 2023 Feb; 67(2):E3-E5. PubMed ID: 36477882
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
    Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
    N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofersen: First Approval.
    Blair HA
    Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Antisense Oligonucleotide Tofersen for
    Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
    N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
    Oliveira Santos M; de Carvalho M
    Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelitis as a side effect of tofersen therapy in SOD1-associated ALS.
    Reilich P; Schöberl F; Hiebeler M; Tonon M; Ludolph AC; Senel M
    J Neurol; 2024 Apr; 271(4):2114-2118. PubMed ID: 38066205
    [No Abstract]   [Full Text] [Related]  

  • 8. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
    Benatar M; Wuu J; Andersen PM; Bucelli RC; Andrews JA; Otto M; Farahany NA; Harrington EA; Chen W; Mitchell AA; Ferguson T; Chew S; Gedney L; Oakley S; Heo J; Chary S; Fanning L; Graham D; Sun P; Liu Y; Wong J; Fradette S
    Neurotherapeutics; 2022 Jul; 19(4):1248-1258. PubMed ID: 35585374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18 months.
    Meyer T; Schumann P; Weydt P; Petri S; Weishaupt JH; Weyen U; Koch JC; Günther R; Regensburger M; Boentert M; Wiesenfarth M; Koc Y; Kolzarek F; Kettemann D; Norden J; Bernsen S; Elmas Z; Conrad J; Valkadinov I; Vidovic M; Dorst J; Ludolph AC; Hesebeck-Brinckmann J; Spittel S; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2024 Sep; 70(3):333-345. PubMed ID: 39031772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory onset of amyotrophic lateral sclerosis in a pregnant woman with a novel SOD1 mutation.
    Masrori P; Ospitalieri S; Forsberg K; Moens TG; Poesen K; Race V; Brännström T; Andersen PM; Thal DR; Van Damme P
    Eur J Neurol; 2022 Apr; 29(4):1279-1283. PubMed ID: 35253968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of
    van Roon-Mom W; Ferguson C; Aartsma-Rus A
    Nucleic Acid Ther; 2023 Aug; 33(4):234-237. PubMed ID: 37581487
    [No Abstract]   [Full Text] [Related]  

  • 12. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
    Saini A; Chawla PA
    Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis.
    Tokuda E; Takei YI; Ohara S; Fujiwara N; Hozumi I; Furukawa Y
    Mol Neurodegener; 2019 Nov; 14(1):42. PubMed ID: 31744522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients.
    Sabatelli M; Cerri F; Zuccarino R; Patanella AK; Bernardo D; Bisogni G; Tanel R; Sansone V; Filosto M; Lattante S; Martello F; Doronzio PN; Stano S; Zanfini BA; Coccia M; Costantini EM; Lizio A; Lucioli G; Padovani A; Merlini GP; Conte A
    J Neurol; 2024 Aug; 271(8):5177-5186. PubMed ID: 38829431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [SOD1 gene therapy delays ALS disease progression].
    Forsberg K; Karlsborg M; Salvesen L; Svenstrup K; Winroth I; Berntsson H; M Andersen P
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38666665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HtrA2/Omi-immunoreactive intraneuronal inclusions in the anterior horn of patients with sporadic and Cu/Zn superoxide dismutase (SOD1) mutant amyotrophic lateral sclerosis.
    Kawamoto Y; Ito H; Kobayashi Y; Suzuki Y; Akiguchi I; Fujimura H; Sakoda S; Kusaka H; Hirano A; Takahashi R
    Neuropathol Appl Neurobiol; 2010 Jun; 36(4):331-44. PubMed ID: 20202124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
    Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
    Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS.
    Wuolikainen A; Moritz T; Marklund SL; Antti H; Andersen PM
    PLoS One; 2011 Apr; 6(4):e17947. PubMed ID: 21483737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.
    Winer L; Srinivasan D; Chun S; Lacomis D; Jaffa M; Fagan A; Holtzman DM; Wancewicz E; Bennett CF; Bowser R; Cudkowicz M; Miller TM
    JAMA Neurol; 2013 Feb; 70(2):201-7. PubMed ID: 23147550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
    Abati E; Bresolin N; Comi G; Corti S
    Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.